89bio's Participation in Healthcare Conferences
89bio, Inc., a pioneer in developing therapies for liver and cardiometabolic diseases, is gearing up for a significant engagement at an upcoming healthcare conference.
About the Conference
The Leerink Partners Global Healthcare Conference is an important event where stakeholders from the biopharmaceutical field gather. This year, 89bio's management team will be participating in a fireside chat. It is set to take place at 4:20 PM EST on a specific day in March.
Engagement Opportunities
The event will not only include discussions but will also present opportunities for one-on-one investor meetings, further enhancing investor relations and stakeholder engagement.
89bio's Mission
89bio is committed to advancing ground-breaking therapies. The company's work primarily focuses on patients suffering from liver and cardiometabolic diseases, areas where treatment options are often lacking or inadequate.
Key Therapies Under Development
Currently, 89bio is in Phase 3 trials for its lead candidate, pegozafermin. This innovative therapy targets metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. It also includes treatment for severe hypertriglyceridemia (SHTG), showcasing the company's dedication to addressing critical health needs.
Innovations and Technologies
Pegozafermin is characterized by its unique glycoPEGylated technology, which focuses on optimizing the stability and activity of the therapy. This potentially best-in-class fibroblast growth factor 21 (FGF21) analog boasts an extended half-life, which may enhance patient outcomes.
Company Background
Founded and headquartered in San Francisco, 89bio is not just a company; it's a mission-driven organization aiming to transform the treatment landscape for patients. The company's commitment extends beyond just developing drugs; they are dedicated to ensuring that patients have access to the best possible treatment options.
Future Prospects
With innovative therapies and a clear focus on unmet medical needs, 89bio is poised for growth. The participation in the Leerink Partners Global Healthcare Conference is a strategic move to forge stronger connections within the investment community, showcasing their advancements and future directions.
Stay Informed
For those interested in exploring further or keeping up with 89bio’s developments, the company’s website offers regular updates and insights into ongoing progress in their clinical trials and therapeutic advancements.
Frequently Asked Questions
What is the significance of the Leerink Partners Global Healthcare Conference?
This conference serves as a platform for biopharmaceutical companies to engage with investors and share insights about advancements in the healthcare space.
What types of therapies does 89bio focus on?
89bio primarily focuses on therapies for liver diseases and cardiometabolic conditions, aiming to provide innovative treatment options for patients.
What is pegozafermin?
Pegozafermin is 89bio’s lead candidate currently in Phase 3 trials, targeting significant metabolic diseases including MASH and severe hypertriglyceridemia.
How can investors keep updated on 89bio?
Investors can visit 89bio's official website where updates, press releases, and information about clinical trials are provided.
Who can I contact for investor relations at 89bio?
For any inquiries regarding investments, interested parties can reach out to the investor contact, Annie Chang, via the email provided on their website.
